Register
Login:
Share:
Email Facebook Twitter

Is the Bull Market over? Andre Minassian says no! Watch here

Is the Bull Market over? Andre Minassian says no!


Sareum Share Chat (SAR)



Share Price: 0.85Bid: 0.80Ask: 0.90Change: -0.025 (-2.86%)Faller - Sareum
Spread: 0.10Spread as %: 12.50%Open: 0.875High: 0.875Low: 0.825Yesterday’s Close: 0.875


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Thoth2
Posts: 1,223
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.85
Some differences
Sun 23:19
If i may opine on why we are different (whilst acknowleding its aim and biotech
So of course you can lose the lot.
1. For a chance of shitloads you need it to be scaleable. Which means
Patent protection and royalties. This rules out mist services businesses.
2. Mass market.
3. Is it an area of research validated by experts. As an exame
Efamol. Patented everything to do with fatty acids. No one else did
Because it turned out to be a duff area. Similarly summit and c-diff
Looks like a great product with unmet need. No one seems
Interested. By contrast several big boys have chased chk1 and
Tyk2 and failed.
4. Quality of partnerships. Im an amateur. Do the experts hook
Up on the research who know their area in detail. Cruk. Icr. SRI are
Undoubtedly.
5. Best in class. It really is winner takes it all. The drug with least
Side effects vs competitor wins. BMS dropped out of lung cancer
This weekend because opdivo is no better than keytruda after
Billions spent. Chk1 seems to be better so far. Tyk2 seems better
But vernalis have a chk1 inhibitor available to licence for several
Years with no takers (i assume its not better).
Lots of uk bios have also ran products. Or research in areas the
Mainstream arent that interested in.
Frquently they concert to become services businesses to extend
Their shelf life.
But this is a pure IP play. And a bet that the molecules are in fact
Best in class.
Our master patent is already referenced by 27 patents from other
Companies including takeda. Millenium. Gsk. Incyte. Acertas
Nimbus.
So the science looks good. And the commercial interest is in our
Area.
But of course its higher risk and not for widows or orphans
 
potnak
Posts: 491
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.85
RE: Potnak
Sun 22:39
I believe SAR will come good. I have 2 millions shares so I really hope they do but I will be happy with 5p a share. If you have time tomorrow, have a surf round some other AIM minnows. Every one of them has a group of investors who think they are invested in the next 100 bagger, the best thing since sliced bread and most of them will lose most of their investment. If you're constantly dreaming of a pound a share then a more realistic 5 or 10p share may be a disappointment, if and when it hopefully comes.
batonrouge
Posts: 424
Off Topic
Opinion:No Opinion
Price:0.85
Potnak
Sun 21:07
Oil companies and Bio companies are alike in some ways. They view the geo phys make a decision to drill and hope for the best. Most times they lose. We more or less do the same with chemical compounds. Most times we lose - but as Thoth says a small percentage come through and the company multibags !
JonTangle
Posts: 301
Off Topic
Opinion:No Opinion
Price:0.85
RE: Someone give me a number.
Sun 19:15
BP are paying around $3m dollars A DAY as a result of the Macondo oil spill.

They will be paying that for a period of 18 years.

Despite that and the fall in POO they've maintained the dividend.

If we currently had to place our hands on $3m a day, we'd not even have the funds to see much more than the early hours of day 2! 😂
potnak
Posts: 491
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.85
RE: Someone give me a number.
Sun 19:02
I'm. Not deramping but if oil companies fail to find oil, they drill elsewhere and the resulting find had a tangible value. Drugs however don't make a single penny until approved. Chalk and cheese.
Arbitrage
Posts: 969
Observation
Opinion:No Opinion
Price:0.85
licensing deal comparative info . .
Sun 18:19
SHAT2
Posts: 960
Observation
Opinion:Strong Buy
Price:0.85
View Thread (3)
RE: Someone give me a number.
Sun 01:52
Hi Every one B.P has 19.473.29 billion shares in issue at a price of 498.35 has we only have 2.645.22 billion shares in issue so looking at that the share price of SAR could go any where from 0.85 to £10 when I first got into dealing in 1998 my first shares was Dana Petroleum I brought them at 2p and sold them at £6. but they went on to £19 a share. Like I keep saying hold tight to your shares load up on the drops if you can. This company IMOP is another Dana Petroleum SAR is a Game Changer the only draw back is we are just going to have to wait. IMOP GLA.
Lottohopes
Posts: 1,048
Off Topic
Opinion:No Opinion
Price:0.85
RE: Someone give me a number.
Sat 22:04
The important thing is: it HAS happened. I think it's possible. Cancer, autoimmune disorders: massive areas. Oceans of human suffering....if FB, Apple and other rubbish can achieve it, anything is possible. Good luck all
Krone
Posts: 24
Off Topic
Opinion:No Opinion
Price:0.85
RE: Someone give me a number.
Sat 16:27
Thank you once again. Obviously you are optimistic that we stand a good chance of success, given the scale of your investment...which is clearly based on very through research and considered opinion. I am encouraged by the degree of optimism from the Sar directors who by definition as research scientists would be cautious and reliant on evidence on which to base their opinions. These guys don't seem the type to get caught up in hype or exaggeration....
Thoth2
Posts: 1,223
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.85
RE: Someone give me a number.
Sat 16:13
Search ELRIG_RobJames for some empirical data on early stage biotech returns. Over half go bust
A small % make 50 fold.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.